Logo_Horizontal_Fill_White_Transparent.png
Neurona Therapeutics Appoints Dr. Nadia Agopyan as Senior Vice President of Regulatory Affairs
June 26, 2024 16:05 ET | Neurona Therapeutics
Neurona Therapeutics Appoints Dr. Nadia Agopyan as Senior Vice President of Regulatory Affairs
arvinas_logoART_lg.jpg
Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2
June 21, 2024 07:00 ET | Arvinas Inc.
– Preclinical data for ARV-393 presented at the European Hematology Association 2024 Annual Congress showed anti-tumor activity in models of B-cell lymphoma –  – Preclinical data presented at the...
Ian Taylor, Ph.D.
Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer
June 17, 2024 07:00 ET | Arvinas Inc.
NEW HAVEN, Conn., June 17, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation,...
Logo_Horizontal_Fill_White_Transparent.png
Neurona Therapeutics Appoints Dr. Manher Joshi as Chief Medical Officer
June 11, 2024 16:05 ET | Neurona Therapeutics
Neurona Therapeutics Appoints Dr. Manher Joshi as Chief Medical Officer
Quicktome Personalized Brain Connectomic Analysis
AI Brain Health Leader Omniscient Closes Series C Funding Round
June 11, 2024 11:00 ET | Omniscient Neurotechnology
Omniscient secures Series C funding to expand Quicktome® platform, advancing connectomics for improved brain health diagnostics and treatments.
arvinas_logoART_lg.jpg
Arvinas to Participate in Upcoming Investor Conferences
June 03, 2024 16:30 ET | Arvinas Inc.
NEW HAVEN, Conn., June 03, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
PN LOGO.jpg
Precision Neuroscience Announces World Record for Number of Electrodes Placed On Human Brain
May 28, 2024 09:00 ET | Precision Neuroscience
NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Brain–computer interface company Precision Neuroscience Corporation (Precision) and a neurosurgery team from the Mount Sinai Health System now hold the...
Logo_Horizontal_Fill_White_Transparent.png
Neurona Therapeutics to Participate in Jefferies Global Healthcare Conference
May 28, 2024 08:00 ET | Neurona Therapeutics
Neurona Therapeutics to Participate in Jefferies Global Healthcare Conference
PN LOGO.jpg
Precision Neuroscience Expands Clinical Research In Brain–Computer Interface
March 22, 2024 08:30 ET | Precision Neuroscience
NEW YORK, March 22, 2024 (GLOBE NEWSWIRE) -- Brain–computer interface (BCI) company Precision Neuroscience Corporation (Precision) today announced the launch of two new clinical study sites, at...
NodThera_logo.jpg
NodThera’s NLRP3 Inhibitor NT-0796 Reverses Neuroinflammation in Parkinson’s Disease Phase Ib/IIa Trial
March 07, 2024 07:00 ET | NodThera
NodThera Ltd (“NodThera” or the “Company”) NodThera’s NLRP3 Inhibitor NT-0796 Reverses Neuroinflammation in Parkinson’s Disease Phase Ib/IIa Trial Brain-penetrant NLRP3 inflammasome inhibitor...